Group 1 - The core viewpoint of the report is that Zhongyin Securities has given a "buy" rating for Tianshili (600535.SH) based on its promising clinical progress and market potential [2] - The company’s P134 product is noted to be at the forefront of clinical development, indicating strong potential for future success [2] - The global market for GBM (glioblastoma) is substantial, and the company is expected to explore new treatment methods, enhancing its growth prospects [2] - The company is increasing its investment in research and development, which is viewed positively in terms of advancing its product pipeline [2]